Paper Details

  1. Home
  2. Paper Details

Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).

Author: RojasCamilo, SlusherBarbara S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Rolanpitant, a neurokinin-1 (NK1) receptor antagonist, has shown promise in improving the control of chemotherapy-induced nausea/vomiting (CINV). The fixed-dose combination product NEPA, composed of the NK1RA netupitant and the 5-HT3RA palonosetron, has also been shown to improve control of CINV in the acute, delayed, and overall phases.
Paper Details　
Original Abstract of the Article :
Many patients undergoing moderately or highly emetogenic chemotherapy experience chemotherapy-induced nausea/vomiting (CINV) and report reduced daily functioning, despite prophylaxis with antiemetic drugs. While modern antiemetics have largely alleviated acute emesis, management of nausea and delaye...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ctrv.2015.09.005

データ提供：米国国立医学図書館（NLM）

Chemotherapy-Induced Nausea and Vomiting: New Approaches to a Challenging Condition

Chemotherapy-induced nausea and vomiting (CINV) is a common and distressing side effect of cancer treatment. This review article explores the pathophysiological mechanisms of CINV and the latest advancements in antiemetic therapy. The focus is on the use of neurokinin-1 (NK1) receptor antagonists (RAs), particularly rolapitant and the fixed-dose combination product NEPA (netupitant/palonosetron). The authors highlight the effectiveness of these new agents in controlling delayed and overall CINV when added to standard 5-HT3RA regimens. This review provides an insightful perspective on the evolving landscape of CINV management.

New Hope for Reducing Chemotherapy-Induced Nausea and Vomiting

The development of NK1 receptor antagonists like rolapitant and NEPA represents a significant step forward in managing CINV. These agents, when used in combination with standard 5-HT3 receptor antagonists, offer improved control over both delayed and overall CINV, enhancing the quality of life for patients undergoing chemotherapy. This advancement is a testament to ongoing research efforts to alleviate the debilitating side effects of cancer treatment.

Navigating Chemotherapy Side Effects: Finding Balance in the Sand

Chemotherapy can be a challenging journey, and managing its side effects is a crucial part of the process. This review emphasizes the importance of exploring new and innovative treatments to improve the patient experience. By incorporating NK1 receptor antagonists into treatment plans, healthcare providers can strive to minimize the discomfort associated with chemotherapy and ensure a more comfortable and effective treatment journey for their patients.

Dr. Camel's Conclusion

The fight against cancer is like navigating a treacherous desert, where every step requires resilience and strength. This review sheds light on new weapons in our arsenal to combat the challenges of chemotherapy-induced nausea and vomiting. The development of NK1 receptor antagonists, like a refreshing spring in the desert, offers hope for a more tolerable and manageable treatment journey for patients battling cancer.
Date :
  1. Date Completed 2016-03-07
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

26442475

DOI: Digital Object Identifier

10.1016/j.ctrv.2015.09.005

Related Literature

Article Analysis
・Effects of rolapitant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.